Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vascana in Secondary Raynaud's Phenomenon
NCT02688270Phase 2Completed
- Sponsor
- Covis Pharma
- Start
- Jun 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MQX-503 in Raynaud phenomenon, sponsored by Covis Pharma. Started Jun 2016; status: completed.
02
Drugs
MQX-503
03
Conditions
Raynaud phenomenon
Beyond the preview
Go deeper on NCT02688270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02688270.